EFFECT OF TUMOR-ASSOCIATED TISSUE EOSINOPHILIA ON SURVIVAL OF WOMEN WITH STAGE-IB CARCINOMA OF THE UTERINE CERVIX

被引:37
作者
BETHWAITE, PB
HOLLOWAY, LJ
YEONG, ML
THORNTON, A
机构
[1] WELLINGTON CLIN SCH MED,DEPT PATHOL,WELLINGTON,NEW ZEALAND
[2] WELLINGTON CLIN SCH MED,DEPT MED,WELLINGTON,NEW ZEALAND
关键词
D O I
10.1136/jcp.46.11.1016
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims-To examine the survival of a group of women with stage IB invasive carcinoma of the uterine cervix, divided according to the expression of tumour associated tissue eosinophilia (TATE). Methods-Histological material from 81 women with stage IB squamous and adenosquamous cervical carcinomas before radiotherapy was assessed for the extent of tissue stromal eosinophilia, quantified using antibodies to human major basic protein. Results-Twenty eight (38%) of the cases demonstrated TATE of over 30 eosinophils/mm2, with 12 (16%) having greater than 100 eosinophils/mm2. Eleven women in the series developed distant spread or recurrent pelvic disease, this group having a stromal eosinophil density significantly less (13.8/mm2) than the remainder (69.9/mm2) (p = 0.03). The acturial five year survival rate for women with a tumour eosinophil density over 30/mm2 was 92% compared with 70% with a density under 30 mm2, with a significant difference in the survival curves for these two groups (p = 0.03). Conclusions-As a univariate parameter, a tumour associated tissue eosinophilia of at least modest proportions is associated with statistically improved survival in women with stage IB cervical carcinomas.
引用
收藏
页码:1016 / 1020
页数:5
相关论文
共 24 条
[1]  
AYHAN A, 1992, EUR J SURG ONCOL, V18, P264
[2]  
BAILAR JOHN C., 1966, NAT CANCER INST MONOGR, V19, P385
[3]   THE PROGNOSIS OF ADENOSQUAMOUS CARCINOMAS OF THE UTERINE CERVIX [J].
BETHWAITE, P ;
YEONG, ML ;
HOLLOWAY, L ;
ROBSON, B ;
DUNCAN, G ;
LAMB, D .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (09) :745-750
[4]  
BOSTROM SG, 1981, CANCER, V47, P2887, DOI 10.1002/1097-0142(19810615)47:12<2887::AID-CNCR2820471223>3.0.CO
[5]  
2-3
[6]  
Dalal B I, 1992, Clin Oncol (R Coll Radiol), V4, P18, DOI 10.1016/S0936-6555(05)80766-6
[7]  
GLEICH GJ, 1979, J IMMUNOL, V123, P2925
[8]  
HEALY TM, 1974, NEW ENGL J MED, V291, P794
[9]  
HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P557
[10]  
IWASAKI K, 1986, CANCER, V58, P1321, DOI 10.1002/1097-0142(19860915)58:6<1321::AID-CNCR2820580623>3.0.CO